NanoLogix Develops Multi-Well, Microplate Reader Variant of its BioNanoFilter Diagnostics

NanoLogix, a biotechnology company focusing on rapid diagnostics, has reported that the company’s research and development team together with researchers from the University of Texas Health Science Center - Houston (UTHSC-Houston) is creating a multi-well, microplate reader version of NanoLogix’s BioNanoFilter (BNF) diagnostics for large volume lab conditions.

Preliminary study of the multi-well plates demonstrates very rapid live-threat results just as NanoLogix’s standard BNF technology. The company will display its BioNanoPore (BNP) and BNF technologies at the 112th General Meeting of the American Society for Microbiology, which will be held from June 16 to 19, 2012, in San Francisco, USA.

Results from a recently concluded clinical study using NanoLogix technology will also be discussed at the ASM General Meeting on June 17, 2012. UTHSC-Houston’s Dr. Jonathan Faro will deliver the presentation on the clinical study results, which concentrated on detection of Group B Streptococcus’ antibiotic sensitivity during pregnancy. Findings confirmed that NanoLogix diagnostics constantly delivered results within a 4-6 h window, which is significantly shorter when compared to typical culturing times of 48-72 h.

At present, formatting of the clinical study description and results is in process for peer-review publication and for the US FDA acceptance to use NanoLogix technology as a non-invasive diagnostic technology. Latest research and development activities have also focused on significantly improving NanoLogix’s portfolio of bacteria and protozoa detection technologies.

A key independent, third-party research lab has recently concluded the Tuberculosis (TB) detection using NanoLogix’s BNP and BNF technologies. NanoLogix’s BNP technology was able to detect live-threat TB within 4-5 days when compared to 21-84 days using standard culture. NanoLogix’s BNF technology was able to detect and identify TB in below 2 h. FDA submittal and peer-reviewed publication are waiting for outcomes from both BNP and BNF TB studies.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback